Engineers Gate Manager LP Savara Inc Transaction History

Engineers Gate Manager LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $24,363 - $120,275	-10,280 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$6.71 - $8.6 $55,706 - $71,397	-8,302 Reduced 44.68%	10,280 $76,000
Q4 2018 Feb 14, 2019	BUY	$6.27 - $10.92 $5,141 - $8,954	820 Added 4.62%	18,582 $141,000
Q3 2018 Nov 01, 2018	BUY	$10.49 - $12.87 $186,323 - $228,596	17,762 New	17,762 $198,000
Q2 2018 Aug 03, 2018	SELL	$8.55 - $13.76 $178,147 - $286,703	-20,836 Closed	0 $0
Q1 2018 May 07, 2018	BUY	$8.99 - $14.95 $187,315 - $311,498	20,836 New	20,836 $192,000

128

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $310M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.